Date: 2012-07-16
Type of information: Initiation of preclinical development
phase:
Announcement: publication of data on 2B3-201 for neuroinflammation in the Journal of Controlled Release.(Gaillard
et al., 2012; http://www.ncbi.nlm.nih.gov/pubmed/22732475)
Company: to-BBB (The Netherlands)
Product: 2B3-201 (brain-targeted liposomal methylprednisolone)
Action mechanism:
Disease: neuroinflammation
Therapeutic area: Inflammatory diseases - Neurodegenerative diseases
Country:
Trial details:
Latest
news: to-BBB, the Dutch brain drug delivery company, has published data on its second product, 2B3-201 for neuroinflammation in the Journal of Controlled Release. to-BBB’s product 2B3-201 (brain-targeted liposomal methylprednisolone) is being developed for neuroinflammation, which plays an important role in several brain diseases. Together with the Blood-Brain Barrier group at the VU Medical Center in Amsterdam, to-BBB has investigated the efficacy of 2B3-201 in an animal model of Multiple Sclerosis (MS). In addition to MS, 2B3-201 has also shown therapeutic benefit in models of neuropathic pain, lysosomal storage diseases and ALS.
to-BBB is scaling up 2B3-201 with manufacturing partner TTY Biopharm (Taiwan) and will engage in preclinical toxicity studies later this year. This will allow a “first in human” study with 2B3-201 in 2013. The Dutch government agency Agentschap NL has granted support to this product development path with an Innovation Credit, covering 35% of the development costs. This consists of an initial investment of more than €500,000 for the preclinical development phase. The company has an option to apply for additional credits for clinical development of 2B3-201.
